CD274 and neoplasm: Understanding the importance of immune checkpoints in blocking tumor recognition has led to development of novel immunotherapies targeting the cytotoxic T-lymphocyte-associated protein (CTLA-4, CD 152), the programmed cell death protein-1 (PD-1, CD279) and its ligand programmed death ligand 1 (PD-L1, CD274) [7].